Cancer Biological Therapy Market: Global Industry Analysis and Forecast (2023-2029)

The Cancer Biological Therapy Market size was valued at USD 126.46 Billion in 2022 and the total Cancer Biological Therapy Market revenue is expected to grow at a CAGR of 7.6 % from 2023 to 2029, reaching nearly USD 203.07 Billion.
Cancer Biological Therapy Market Overview
Cancer Biological Therapy, also known as immunotherapy, harnesses the patient's immune system as a formidable weapon against cancer cells. This treatment approach employs biological agents like monoclonal antibodies, cytokines, and immune checkpoint inhibitors, either activating the immune system's assault on cancer cells or directly targeting them.

The realm of biological therapy is progressively gaining significance in cancer research and treatment. Ongoing advancements in innovative therapies are continuously broadening the horizons for cancer patients. The growth of this sector is propelled by the rising incidence of cancer and the constant evolution of pioneering biologic therapies, thus expanding the array of options accessible to patients.
Cancer Biological Therapy Market Snapshot
To know about the Research Methodology :- Request Free Sample Report

Cancer Biological Therapy Market Scope and Research Methodology

The market report on Market provides information on the market drivers, challenges, restraints, market penetration, and opportunities in the Cancer Biological Therapy Market. Research can also include analysis of market trends, such as the number of clinical trials underway, the success rates of different drug candidates, and the financial performance of key players in the market. The key findings of the report include market size and forecasts equipped with current environmental and other ongoing developments that affect the Cancer Biological Therapy industry.

The Market was segmented into Drug type, therapy type, cancer type, and end-user which is presented with the help of graphs and figures for a better understanding of the fastest-growing segments. The bottom-up approach is used for market estimations which were validated by various segments. Key players are concentrated in developed regions for which regional partnership and distribution agreements are in place. Research such as SWOT, PESTLE, and Porter’s Five Force analysis were used to understand the underlying factors affecting.
Cancer Biological Therapy Market Dynamics
Explosive Demand for Revolutionary Cancer Treatment to Boost the Market Growth

The market for revolutionary cancer treatment is experiencing explosive demand and robust growth due to several intertwined factors. The emergence of breakthrough biotechnologies and genomics has paved the way for highly tailored therapies, targeting unique genetic and molecular aspects of cancers. This personalized approach has garnered immense attention and trust from patients and healthcare providers alike, driving the market growth. Also, the demonstrated effectiveness of these innovative treatments, such as monoclonal antibodies, immune checkpoint inhibitors, and CAR-T cell therapies, has fuelled a surge in demand for their remarkable outcomes and reduced side effects compared to conventional treatments. Increased investments in research, development, and infrastructure by both biotech and pharmaceutical companies have accelerated the availability and accessibility of these treatments, solidifying the trajectory of market expansion.

High cost of biological therapies creates a competitive environment to boost the market growth

The higher cost of biological therapies, arising from intricate manufacturing, extensive research, and patent protection, poses challenges to patient accessibility and healthcare affordability. This fosters a competitive landscape among pharmaceutical companies, driving pricing strategies like concessions and rebates to enhance market presence. This cost dynamic significantly influences the Cancer Biological Therapy market. With biologic therapies gaining approval, intensified competition and pricing pressures emerge, potentially impacting established firms. Patent expirations pave the way for biosimilar alternatives, affecting revenue and market share. This dynamic environment affects innovation and market contours, as pharmaceutical entities strive to develop and promote biologic therapies across diverse cancer types, emphasizing competition and patent dynamics as key drivers.

Increasing Adoption of Targeted Therapies to drive the Cancer Biological Therapy market

Biologic therapies, referred to as targeted treatments, possess the unique ability to pinpoint cancer cells while sparing healthy ones, rendering them a remarkably potent choice for diverse cancer types. In contrast to conventional chemotherapy's substantial side effects, these therapies offer enhanced precision, yielding superior results with minimized toxicity. The oncology realm has witnessed a growing integration of targeted biologics, propelling the expansion of the Cancer Biological Therapy market. Advancements in biologic innovation, yielding heightened effectiveness and safety, coupled with the broader application of established treatments, have additionally catalyzed market growth.

Cancer Biological Therapy Market Restraints

The Cancer Biological Therapy Market encounters restraints due to Biologic therapies for cancer are generally more expensive than traditional chemotherapy or radiation therapy. The high cost of biologic therapies can limit patient access, particularly in regions with limited healthcare resources or for patients without insurance coverage. This also leads to payer scrutiny and reimbursement challenges, which impact market growth. The intricate manufacturing processes, extensive research and development, and patent protection contribute to elevated expenses. These financial burdens may hinder patient affordability and strain healthcare systems. Furthermore, as biosimilar alternatives enter the scene upon patent expirations, established biologic therapies face potential revenue and market share challenges. These complexities emphasize the need for balancing innovation with cost-effectiveness in the pursuit of optimal cancer biological therapy outcomes.
Cancer Biological Therapy Market Segmentation Based on drug class
The market includes cytotoxic drugs, targeted drugs, hormonal drugs, and others. The targeted drugs segment held the largest market share in 2022 and is expected to dominate the market during the forecast period. Due to their precision in targeting cancer cells, resulting in improved efficacy and reduced side effects. This class of drugs harnesses advancements in biotechnology to provide a more tailored and effective approach to cancer treatment compared to traditional cytotoxic and hormonal drugs.
Global Cancer Biological Therapy Market By Drug Class (USD Bn.) in 2022


Based on therapy, the Market includes chemotherapy, targeted therapy, immunotherapy the targeted therapy, and others. The immunotherapy segment held the largest market Revenue share in 2022 and is expected to dominate the market during the forecast period. due to its revolutionary approach of leveraging the body's immune system to target and combat cancer cells specifically. Its ability to produce lasting responses and potential cures, along with reduced side effects compared to traditional treatments like chemotherapy, has positioned immunotherapy as a forefront contender. This approach holds promise for various cancer types and has gained significant attention and investment, driving its dominance in the cancer therapy landscape.
Cancer Biological Therapy Market Revenue Share ,by Therapy Type (in %) in 2022

Cancer Biological Therapy Market Regional Insight
North America held the largest Market and is expected to dominate the market during the forecast period due to its robust healthcare infrastructure, substantial investment in research and development, and widespread adoption of innovative medical technologies. The region's leading pharmaceutical and biotechnology companies drive advancements in biologic therapies. Additionally, a supportive regulatory environment expedites drug approvals.

High prevalence of cancer cases and growing awareness among patients and healthcare professionals further fuel demand. Access to skilled healthcare practitioners, clinical expertise, and extensive patient databases contribute to North America's dominance, as it continues to pave the way in revolutionizing cancer treatment through biological therapies.

The expansion of the North American market is being fueled by an increase in government initiatives and R&D spending, a proliferation of producers of biological cancer drugs and vaccines, rising disposable income, accessible cancer treatment centers, and expanding health insurance coverage for serious illnesses.

Asia Pacific is expected to the fastest-growing region

In 2022, the Asia-Pacific region is set to experience rapid expansion in the Market, fueled by mounting cancer rates, augmented healthcare spending, and enhanced medical infrastructure in countries like China, India, and Japan. With a substantial patient base, this region presents a notable market prospect for biotech and pharmaceutical firms, solidifying its status as a thriving hub for growth and innovation.

Cancer Biological Therapy Market Competitive landscape

The leading key players in the Market are Merck& Co Inc. Amgen, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Abbvie Inc., Novartis International Ag, Pfizer, Inc., These players have adopted various strategies to increase their market penetration and strengthen their position in the Cancer Biological Therapy industry. Most of them have invested significantly in research and development activities programs. For the expansion of product portfolio and M & A are the key strategies adopted by leading companies. Advancement and acquisition are the common strategies used by major market players for the expansion of business.

Predictive biologic therapy and Cancer Research Horizons, have collaborated to drive cancer drug development using the former’s PEDAL platform. This partnership has been using the artificial intelligence and machine learning platform, PEDAL technology, to determine which cancer types and patient populations. The Janssen Pharmaceutical Companies of Johnson & Johnson received the United States Food and Drug Administration approval for CARVYKTI. This biologic medicine is used for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Top Global Keyplayers in Cancer Biological Therapy Market Share(%) in 2018-2022

Cancer Biological Therapy Market Scope: Inquire before buying



Global Cancer Biological Therapy Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 5 Bn.


Forecast Period 2023 to 2029 CAGR:
4.5%
Market Size in 2029:
US $ 10 Bn.


 Segments Covered:
by Therapy Type
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Other Treatment Types


by Drug Class
Cytotoxic Drugs
Targeted Drugs
Hormonal Drugs
Others


by End User
Hospitals
Retail Pharmacy
Specialized Cancer Treatment
Online Pharmacy



Cancer Biological Therapy Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and the Rest of APAC)
South America (Brazil, Argentina Rest of South America)
Middle East & Africa (South Africa, GCC, Egypt, Nigeria and the Rest of ME&A)
Cancer Biological Therapy Market, Key Players are
1. Roche
2. Bristol Myers Squibb
3. Merck & Co., Amgen
4. Novartis
5. Johnson & Johnson
6. AstraZeneca
7. Gilead Sciences
8. AbbVie,
9. Celgene
10.Pfizer
11. Amgen
12. Celgene Corporation
13. Gilead Sciences
Frequently Asked Questions:
1] What is the growth rate of the Global Cancer Biological Therapy Market?
Ans. The Global Cancer Biological Therapy Market is growing at a significant rate of 7.6 percent over the forecast period.

2] Which region is expected to dominate the Cancer Biological Therapy Market?
Ans. North American region is expected to dominate the Cancer Biological Therapy Market over the forecast period.

3] What is expected Global Cancer Biological Therapy Market size by 2029?
Ans. The market size of the Cancer Biological Therapy Market is expected to reach USD 203.07 Bn by 2029.

4] Who are the top players in the Cancer Biological Therapy Market?
Ans. The major key players of the Global Market are Merck& Co Inc. Amgen, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, and Johnson & Johnson.

5] What is the study period of this market?
Ans: The Global Market is studied from 2022 to 2029.